|Articles|October 19, 2021

FDA Issues EUA for New Saliva Sample Collection for Thermo Fisher Device

The company announced the Emergency Use Authorization (EUA) for use with its Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

The Food and Drug Administration (FDA) has issued Thermo Fisher Scientific an EUA to run COVID-19 tests from saliva samples collected with their Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

According to the company, SDNA saliva collection devices are self-contained systems that provide sample consistency and long-term stability while protecting DNA and RNA transcripts post-collection to help ensure accurate test results with only two milliliters of saliva. This gives laboratories the ability to scale up COVID-19 PCR testing and process up to 8000 samples a day.

"With the increase of COVID-19 cases due to more transmissible variants such as the Delta variant, routine testing for SARS-CoV-2 remains an effective strategy to curb the pandemic," Manoj Gandhi, senior medical director of genetic testing solutions, Thermo Fisher Scientific, said. "By enabling labs and public health officials with additional flexibility in sample collection on a high-throughput system, we are improving their ability to meet the increased demand which helps to monitor the spread of COVID-19 and, eventually, save lives."

The Amplitude Solution is a molecular diagnostic system with high-throughput capabilities can be flexed to address testing needs for companies, schools, universities and communities. The kit's multi-gene target design and updated interpretive software is also designed to help labs detect SARS-CoV-2 variants.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.